226 Studies Now Enrolling
Menu
Search
Status
Medical Condition
- Show all (662)
- Autoimmune Disorders (1)
- (-) Blood Disorders (4)
- Cancer
(564)
- Bladder Cancer (13)
- Brain Cancer (12)
- Breast Cancer (60)
- Gastrointestinal (10)
- Gynecologic Cancer (30)
- Head and Neck Cancer (4)
- (-) Kidney Cancer (7)
- Leukemia (64)
- Liver Cancer (4)
- Lung Cancer (57)
- Lymphoma (24)
- Multiple Myeloma (24)
- Pancreatic Cancer (6)
- Prostate Cancer (25)
- Sarcoma (23)
- Skin Cancer (26)
- Solid Tumors (36)
- Thyroid Cancer (1)
- Uveal Melanoma (7)
- COVID-19 (Coronavirus) (1)
- Diabetes (2)
- Ear, Nose and Throat (1)
- Endocrine & Metabolic Disease (1)
- Gastrointestinal and Digestive Diseases (2)
- Healthy Volunteers (7)
- Heart Disease (2)
- Liver Disease (1)
- Neurological Disorders (22)
- Obesity (1)
- Obstetrics & Gynecology (6)
- Pediatrics (41)
- Psychiatric Disorders (1)
- Surgery (1)
- Transplant (3)
- Urology (1)
Displaying 1 - 11 of 11
Condition: Cancer / Kidney Cancer
Investigator: Mark Stein, MD
Status: Closed
This study will test whether cabozantinib in combination with nivolumab plus ipilimumab is more effective (works better) than nivolumab plus ipilimumab alone in treating patients with advanced kidney cancer who have not received prior treatment for their cancer. This study will also examine how…
Condition: Cancer / Kidney Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to determine if the use of immunotherapy nivolumab and the targeted therapy cabozantinib prior to removal of the kidney will increase the number subjects who are without any visible kidney cancer in their body at some point during the course of treatment. The study will also evaluate the changes…
Condition: Cancer / Kidney Cancer
Investigator: Emerson Lim, MD
Status: Closed
This study is for patients who have renal cell carcinoma (RCC; a type of kidney cancer) and are at a high risk of disease coming back (disease recurrence) following either nephrectomy (surgical procedure to remove all or part of a kidney) or metastasectomy (removal of cancerous growth that has…
Condition: Cancer / Kidney Cancer
Investigator: Karie D. Runcie, MD
Status: Closed
The purpose of this study is to study two experimental drugs called canakinumab and spartalizumab produced by Novartis to see if: It is safe and feasible to give canakinumab and spartalizumab prior to radical nephrectomy; canakinumab and spartalizumab can kill cancer cells and bring immune cells into the kidney…
Condition: Cancer / Kidney Cancer
Investigator: Emerson Lim, MD
Status: Closed
We are doing this study to test a drug called MGD009. MGD009 is like an antibody, which is a protein in your blood that helps get rid of germs in your body. MGD009 is made to attach to cancer cells and to T-cells, which are a part of your immune system. Certain T cells have the ability to kill other cells, including…
Condition: Cancer / Kidney Cancer
Investigator: Mark Stein, MD
Status: Closed
This research study is a phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational treatment to learn whether the intervention works in treating a specific disease. Investigational means that the intervention is being studied. The Food and Drug Administration (FDA) has approved Nivolumab as treatment for…
Condition: Cancer / Kidney Cancer
Investigator: Antonio Fojo, MD, PhD
Status: Closed
Axitinib (AG-013736) is an investigational (experimental) drug that is being studied in patients with metastatic pheochromocytoma/paraganglioma. The main goal of this study is to find out if axitinib is able to stop tumors from growing, or shrink tumors in patients with this type of cancer.
Condition: Blood Disorders
Investigator: Mark Heaney, MD, PhD
Status: Closed
This is a Phase 2 study for patients with myelofibrosis previously treated with one or more Janus Kinase(JAK) Inhibitor. A JAK inhibitor targets a certain pathway that may be causing cancer to grow, bystopping or inhibiting the cycle of development of the pathway. There is one JAK inhibitor that has beenapproved for the…
Condition: Blood Disorders
Investigator: Mark Heaney, MD, PhD
Status: Closed
The purpose of this study is to collect information on whether idasanutlin is effective in treating polycythemia vera (a slow-growing blood cancer in which your bone marrow makes too many red blood cells) and what effects, good or bad, idasanutlin has on you. Idasanutlin is an experimental drug, which means Health Authorities…
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
This is a research study for subjects that have been previously treated for systemic light chain (AL)amyloidosis (a disease in which abnormal protein deposits can damage organs and tissues in your body) and nowrequire further treatment. The main purpose of this study is to evaluate the safety and determine the maximum tolerated dose of aninvestigational new…
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to test for any good and bad effects of the study drug called isatuximab. Isatuximab may or may not improve your AL amyloidosis, but it could also cause side effects. Isatuximab is not approved by the Food and Drug Administration (FDA). Isatuximab has been shown to have good effects in some patients with recurring multiple…